Cox-2 inhibitors in mandibular third molar surgery

Area of Science:

• Pharmacology
• Surgical Pain Management
• Inflammation and Pain Pathways

Background:

• Cyclooxygenase (COX) enzymes, COX-1 and COX-2, are key targets for pain and inflammation control.
• Nonselective NSAIDs inhibit both COX-1 and COX-2, leading to potential gastrointestinal side effects.
• COX-2 selective inhibitors (coxibs) aim to provide anti-inflammatory and analgesic effects with a reduced side-effect profile.

Purpose of the Study:

• To evaluate the efficacy of pre-operative versus post-operative rofecoxib administration in managing pain and swelling.
• To compare the effectiveness of timing of administration for a COX-2 selective inhibitor in a surgical context.

Main Methods:

• A randomized study evaluating 50 mg of rofecoxib administered either one hour before or one hour after mandibular third molar surgery.
• Assessment of pain and swelling as primary outcome measures.

Main Results:

• Pre-operative administration of rofecoxib demonstrated more effective control of post-operative pain and swelling.
• The timing of rofecoxib administration significantly impacted its efficacy in this surgical model.

Conclusions:

• Administering rofecoxib pre-operatively is more effective for managing pain and swelling following mandibular third molar surgery.
• Pre-emptive analgesia with COX-2 selective inhibitors may offer improved patient outcomes in oral surgery.